There are a number of co-infections to consider
treating Lyme Disease. It is currently believed these enter the body with the
tick bite. The first two are the ones we commonly see here in Australia. These
two are frequently found on PCR testing after negative serology in Lyme
Mycoplasma including fermentans
(recently re-classified chlamydophila but this
terminolgy is not being widely used yet. It is distinct from STD's)
An emerging bacterial infection in
domestic and farm animals in Australia but now also humans. Serology may
detect this in the meantime. Treatment is azithromycin, rifampicin or Doxycycline.
PCR testing is only available in the US
In Australia we have another genotype of bartonella
causing human disease - more on this imminently
Babesiosis - Human - Usually B. Microti or B.
Duncanii can be found. It is suspected we have a further genotype causing
human infection in Australia.
A good description of this disorder is given at http://emedicine.medscape.com/article/996610-overview
and from The American Family Physician http://www.aafp.org/afp/2001/0515/p1969.html
It is a very serious disease in people who have had a splenectomy.
Treatment is Atavaquone 750mg and
Azithromycin 500mg for 6 to 8 months. There is another
treatment regime with quinine and clindamycin but the serious side effect
profile runs at 72%.
An emerging infectious disease. http://www.cdc.gov/ncidod/eid/vol11no12/05-0898.htm
and a bovine form in Australia http://www.dpi.qld.gov.au/4790_5839.htm
more US info and data http://www.health.state.mn.us/divs/idepc/diseases/anaplasmosis/hcp.html
The acute infection is called tick fever. Treatment is doxycycline 200mg
daily until fever has subsided for 3 days
The practice case load (serologically proven) has all the above infections
including a recently found anaplasmosis in a woman who had not left Australia!
XMRV possible role of a retro
virus - some snippets from current research
In the US they are now finding protomyxzoa
rheumatica, another problematic bacterial infection. We will be keeping a
close eye on developments with this over 2012-2013.